Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (137)	1/4/2018 4:51:13 PM
From: Bladerunner17	Read Replies (2) \| Respond to of 294

I thought the data presented at ASH were pretty good. I thought the Market reaction was unwarranted. I think they could partner at any time. With a market cap under $130 million and enough cash for, at least, another full year, I think this is not a bad time to buy. Furthermore, we may be starting to see the beginning of a strong bull market in small and micro-cap biotech. Just look at ITEK, ADXS, CCXI, ARQL, VYGR, TOCA, ITCI, AUPH, BLCM, JNCE, just to mention some that I follow. I'm sure there are many others. Bladerunner